Unverified50% confidenceBenchmarkExact time
Without evolution enabled, DrugHarness exceeds the previously reported MolClaw-CC results on MolBench by 10.8 percentage points in affinity comparison accuracy and by 55% in the average number of top-three active hits.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/19/2026
First Seen
Valid until: 1/17/2027
Sources
Related Entities
Related Claims
UnverifiedIn real physical laboratory validation of molecular design, the model achieved a hit rate of nearly 50% across 12 targets, compared to the industry average of approximately 10% to 15%.57% similarUnverifiedRoboDojo具身智能测评显示，最强模型得分仅12.8分（人类基准为100分），仿真成功率不足9%，真机成功率12.8%55% similarUnverifiedIn LSCBench, the six models' functional pass rate reached as high as 91.3%, but the highest simultaneous functional and security pass rate was only 25.1%.53% similarUnverifiedThe loss during training is calculated per token, and long samples contribute far more gradient than short samples, so a 10% share of rows can absolutely correspond to more than 50% of the token volume and gradient signal.53% similarUnverifiedWith OPOD, the success rate of small orchestrators improves by an average of 10.0% compared to existing training baselines.52% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1065881API
curl https://kongchang.com/api/v1/knowledge/claims/1065881MCP
get_claim(id=1065881)